{
    "clinical_study": {
        "@rank": "60429", 
        "arm_group": {
            "arm_group_label": "Aripiprazole once-monthly", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "To obtain information on the safety, tolerability and effectiveness of aripiprazole\n      once-monthly in a manner consistent with its intended use in everyday clinical practice in\n      patients with schizophrenia who completed Study 14724A / NCT01795547."
        }, 
        "brief_title": "Aripiprazole Once-monthly in Patients With Schizophrenia", 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients will be recruited among those who complete treatment with aripiprazole in Study\n        14724A / NCT01795547.\n\n        Inclusion Criteria:\n\n          -  The patient is judged to potentially benefit from 24-week treatment with aripiprazole\n             once-monthly according to the clinical opinion of the investigator.\n\n          -  The patient agrees to protocol-defined use of effective contraception.\n\n        Exclusion Criteria:\n\n          -  The patient has been diagnosed with a primary psychiatric disorder other than\n             schizophrenia during Study 14724A / NCT01795547.\n\n          -  The patient has a clinically significant unstable illness diagnosed during Study\n             14724A / NCT01795547.\n\n          -  The patient is at significant risk of harming himself/herself or others according to\n             the investigator's judgement or according to Columbia-Suicide Severity Rating Scale\n             (C-SSRS).\n\n          -  The patient has a disease or takes medication that could, in the investigator's\n             opinion, interfere with the assessments of safety, tolerability or efficacy, or\n             interfere with the conduct or interpretation of the study.\n\n          -  The patient has one or more clinical laboratory test values outside the reference\n             range, based on the blood or urine samples taken during the conduct of Study 14724A /\n             NCT01795547 that are, in the investigator's opinion, of potential risk to the\n             patient's safety.\n\n          -  The patient is, in the investigator's opinion, unlikely to comply with the protocol\n             or is unsuitable for any reason.\n\n        Other inclusion and exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01959035", 
            "org_study_id": "14724B", 
            "secondary_id": "2012-003239-47"
        }, 
        "intervention": {
            "arm_group_label": "Aripiprazole once-monthly", 
            "description": "400 or 300 mg/month; 6 intramuscular (IM) injections starting at Baseline", 
            "intervention_name": "Aripiprazole once-monthly", 
            "intervention_type": "Drug", 
            "other_name": "Abilify\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Aripiprazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 14, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "San Diego", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "92102"
                }, 
                "name": "US006"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Interventional, Open-label, Flexible-dose Extension Study of Aripiprazole Once-monthly in Patients With Schizophrenia", 
        "overall_contact": {
            "email": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S"
        }, 
        "overall_official": {
            "affiliation": "LundbeckClinicalTrials@lundbeck.com", 
            "last_name": "Email contact via H. Lundbeck A/S", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Czech Republic: State Institute for Drug Control", 
                "Estonia: The State Agency of Medicine", 
                "Italy: The Italian Medicines Agency", 
                "Spain: Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios", 
                "Sweden: Medical Products Agency", 
                "United States: Food and Drug Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Number of adverse events", 
                "measure": "Safety and tolerability", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks and 4-week safety follow up"
            }, 
            {
                "description": "Columbia-Suicide Severity Rating Scale (C-SRRS) score", 
                "measure": "Risk of suicidality", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 24 weeks and 4-week safety follow up"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01959035"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Subjective Well-being under Neuroleptics - short version (SWN-S) total score", 
                "measure": "Mean change from Baseline in subjective well-being using SWN-S", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Clinical Global Impression - Severity of Illness (CGI-S) score", 
                "measure": "Mean change from Baseline in clinical global impression", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Quality of Life Scale (QLS) total score", 
                "measure": "Mean change from Baseline in quality of life", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "4 QLS dimension scores", 
                "measure": "Mean change from Baseline in quality of life using QLS", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Tolerability and Quality of Life (TooL) total score", 
                "measure": "Mean change from Baseline in tolerability and quality of life using TooL", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "Arizona Sexual Experience Scale (ASEX) total score", 
                "measure": "Mean change from Baseline to identify individuals with sexual dysfunction", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "description": "The Readiness for Work Questionnaire (WoRQ) total score", 
                "measure": "Mean change from Baseline in the patient's readiness to work", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "H. Lundbeck A/S", 
        "sponsors": {
            "collaborator": {
                "agency": "Otsuka Pharmaceutical Co., Ltd.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "H. Lundbeck A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}